ethyl 5-(2-hexyloxyphenyl)isoxazole-3-carboxylate | 668971-83-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: ethyl 5-(2-hexyloxyphenyl)isoxazole-3-carboxylate
• 英文别名: 5-(2-hexyloxy-phenyl)isoxazole-3-carboxylic acid ethyl ester；Ethyl 5-[2-(hexyloxy)phenyl]isoxazole-3-carboxylate；ethyl 5-(2-hexoxyphenyl)-1,2-oxazole-3-carboxylate
• CAS: 668971-83-3
• 化学式: C₁₈H₂₃NO₄
• 分子量: 317.385
• InChiKey: DFBAPOPKNAJIRC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  23
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  61.6
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl 5-(2-hexyloxyphenyl)isoxazole-3-carboxylate 在 1-羟基苯并三唑 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 、 sodium hydroxide 作用下， 以 乙醇 、 氯仿 为溶剂， 反应 48.75h， 生成 N-(1-adamantyl)-5-(2-hexyloxyphenyl)isoxazole-3-carboxamide
  参考文献：
  名称：

  3-Carboxamido-5-aryl-isoxazoles as new CB2 agonists for the treatment of colitis

  摘要：

  Recent investigations showed that anandamide, the main endogenous ligand of CB1 and CB2 cannabinoid receptors, possesses analgesic, antidepressant and anti-inflammatory effects. In the perspective to treat inflammatory bowel disease (IBD), our approach was to develop new selective CB2 receptor agonists without psychotropic side effects associated to CB1 receptors. In this purpose, a new series of 3-carboxamido-5-aryl-isoxazoles, never described previously as CB2 receptor agonists, was designed, synthesized and evaluated for their biological activity. The pharmacological results have identified great selective CB2 agonists with in vivo anti-inflammatory activity in a DSS-induced acute colitis mouse model. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.06.010
• 作为产物：
  描述：

  ethyl 4-(2-hexoxyphenyl)-2-hydroxy-4-oxo-2-butenoate 在 盐酸羟胺 作用下， 以 乙醇 为溶剂， 反应 2.0h， 以53%的产率得到ethyl 5-(2-hexyloxyphenyl)isoxazole-3-carboxylate
  参考文献：
  名称：

  3-Carboxamido-5-aryl-isoxazoles as new CB2 agonists for the treatment of colitis

  摘要：

  Recent investigations showed that anandamide, the main endogenous ligand of CB1 and CB2 cannabinoid receptors, possesses analgesic, antidepressant and anti-inflammatory effects. In the perspective to treat inflammatory bowel disease (IBD), our approach was to develop new selective CB2 receptor agonists without psychotropic side effects associated to CB1 receptors. In this purpose, a new series of 3-carboxamido-5-aryl-isoxazoles, never described previously as CB2 receptor agonists, was designed, synthesized and evaluated for their biological activity. The pharmacological results have identified great selective CB2 agonists with in vivo anti-inflammatory activity in a DSS-induced acute colitis mouse model. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.06.010

文献信息

• [EN] ANTIBACTERIAL BENZOIC ACID DERIVATIVES<br/>[FR] DERIVES D'ACIDES BENZOIQUES ANTIBACTERIENS
  申请人：UPJOHN CO

  公开号：WO2004018428A1

  公开（公告）日：2004-03-04

  The invention provides antimicrobial agents and methods of using the agents for sterilization, sanitation, antisepsis, disinfection, and treatment of infections in mammals.

  这项发明提供了抗菌剂和使用这些剂进行哺乳动物的消毒、卫生、防腐、消毒和治疗感染的方法。
• Antibacterial benzoic acid derivatives
  申请人：——

  公开号：US20040110802A1

  公开（公告）日：2004-06-10

  The invention provides antimicrobial agents and methods of using the agents for sterilization, sanitation, antisepsis, disinfection, and treatment of infections in mammals.

  这项发明提供了抗微生物药剂及其使用方法，用于哺乳动物的消毒、卫生、防腐、消毒和治疗感染。
• 3-Carboxamido-5-aryl-isoxazoles as new CB2 agonists for the treatment of colitis
  作者：Aurélien Tourteau、Virginie Andrzejak、Mathilde Body-Malapel、Lucas Lemaire、Amélie Lemoine、Roxane Mansouri、Madjid Djouina、Nicolas Renault、Jamal El Bakali、Pierre Desreumaux、Giulio G. Muccioli、Didier M. Lambert、Philippe Chavatte、Benoît Rigo、Natascha Leleu-Chavain、Régis Millet

  DOI：10.1016/j.bmc.2013.06.010

  日期：2013.9

  Recent investigations showed that anandamide, the main endogenous ligand of CB1 and CB2 cannabinoid receptors, possesses analgesic, antidepressant and anti-inflammatory effects. In the perspective to treat inflammatory bowel disease (IBD), our approach was to develop new selective CB2 receptor agonists without psychotropic side effects associated to CB1 receptors. In this purpose, a new series of 3-carboxamido-5-aryl-isoxazoles, never described previously as CB2 receptor agonists, was designed, synthesized and evaluated for their biological activity. The pharmacological results have identified great selective CB2 agonists with in vivo anti-inflammatory activity in a DSS-induced acute colitis mouse model. (C) 2013 Elsevier Ltd. All rights reserved.